2SEVENTY BIO INC (TSVT) Stock Analyst Ratings
USA - NASDAQ:TSVT - US9013841070 - Common Stock
5 USD
+0.01 (+0.2%)
5 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 48% to TSVT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 2% above the current price.
TSVT was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about TSVT.
In the previous month the buy percentage consensus was at a similar level.
TSVT was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-07-29 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-06-27 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-05-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-04-08 | Citigroup | Maintains | Buy -> Buy |
| 2024-03-18 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-01-31 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-01-31 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-20 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-10-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2023-10-12 | Citigroup | Initiate | Buy |
| 2023-09-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-09-13 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2023-09-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-15 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-07-28 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-28 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2023-07-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-05-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-03-17 | Wedbush | Maintains | Outperform |
| 2023-01-24 | Morgan Stanley | Maintains | Overweight |
| 2023-01-20 | Goldman Sachs | Maintains | Buy |
| 2023-01-10 | SVB Leerink | Maintains | Outperform |
| 2022-11-08 | SVB Leerink | Maintains | Outperform |
| 2022-11-08 | Morgan Stanley | Maintains | Overweight |
| 2022-10-31 | Guggenheim | Initiate | Buy |
| 2022-08-15 | Morgan Stanley | Maintains | Overweight |
2SEVENTY BIO INC / TSVT FAQ
What is the average price target for 2SEVENTY BIO INC (TSVT) stock?
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
How do analysts rate 2SEVENTY BIO INC (TSVT)?
The consensus rating for 2SEVENTY BIO INC (TSVT) is 47.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.